Looking at the methylation market from Nuohui’s financial report, Kebai Biotech helps the development of methylation standards

Nuohui Health (6606.HK) released the 2023 mid-year profit forecast on the Hong Kong Stock Exchange on July 10: According to the median of the pre-audit financial data, as of June 30, 2023, the group's revenue in the first half of the year Exceeding the whole year of last year, it reached 820 million yuan, maintaining a high-speed growth of three-digit percentage. Among them, Chang Weiqing's clinical market access and volume increase have accelerated, and its contribution to the group's total revenue has continued to increase, accounting for 60%.

As of June 30, 2023, Chang Weiqing's sales revenue in the first half of the year is expected to range from RMB 480 million to RMB 500 million, an increase of 553.4% to 580.6% over the same period in 2022. As of June 30 in 2022, Chang Weiqing's sales revenue will be RMB 73,600.

As of June 30, 2023, Chang Weiqing's gross profit from sales in the first half of the year is expected to range from RMB 443.7 million to RMB 451.7 million, an increase of 695.2% to 709.5% over the same period in 2022. As of June 30 in 2022, Chang Weiqing's gross profit from sales will be RMB 55.8 million.

Gene methylation detection products

Gene methylation detection products are one of the hottest tracks in the IVD field. Compared with many mature IVD detection kits, methylation detection products have great potential in the field of tumor auxiliary diagnosis/screening, and are compatible with mature Compared with the Red Sea in the IVD detection kit market, although the development of methylated IVD kits is still very complicated, there are many opportunities, such as overtaking at corners, dark horses in the industry, etc., all of which have great opportunities.

At present, there are 20 certified methylation products, and the specific data are shown in Table 1:

At the same time, there are also many products that have entered the clinical trial stage. According to the data analysis of the first quarter of 2021 to 2023 released by Youcikang, there are already 58 products that have entered the clinical trial stage.

Methylation Standards

As a company specializing in the development of molecular diagnostic standards, we have gradually become the preferred supplier of IVD kit manufacturers at home and abroad. During the development process over the years, we have kept pace with the times and launched one after another popular standards. Products, such as a small panel for lung cancer, a large pan-tumor panel, tTMB/bTMB, MSI, HRR/HRD, MRD, etc. Naturally, in 2023, we will also assist in the development of methylation standard products (quality control products and reference products), To meet the needs of domestic and foreign industry customers.

At present, related products are under development. This article serves as a preview, and I will share our views with you first.

Based on the fact that methylation has a clear prospect in the early detection and screening of tumors, we also choose the methylation of tumor-related genes as the research object. Some genes are shown in the following table:

Table 3. Some genes related to tumors are displayed, and the red ones are relatively hot genes=

We will continue to develop corresponding standard products for the above genes. The development ideas are mainly divided into 4 steps:

first step

According to the sequence of the gene, find out the key CGI, combine the structure of the gene transcript, and the relationship with TSS, and preliminarily screen out the key CGI;

second step

Establish an internal primary screening system, combine the selected CGI segment, select a certain range of amplicons, and use common methylation detection methods (such as BSP and pyrosequencing) to detect methylation of multiple amplicons in the target region basic data;

third step

According to the data in the second step, finely judge the useful small amplicon region, develop dPCR in this region, and detect the degree of methylation of the CG;

the fourth step

Based on the methylation of this region and the methylation data of this site, a complete set of reference and quality control system is established.

The above is our internal development of methylation standard ideas, more specific gene cases, we will launch our products in the near future (forecast: the first batch is expected to launch SDC2/SEPTIN9/NDRG4/Twist1).

Welcome new and old friends to call and communicate, and together promote the registration of methylation IVD kits.